Study highlights need for early intervention for behavioral problems

A six-year study that analyzed data from a 25-question screening tool found alarming evidence of unhealthy behavioral trajectories starting as early as age 2 among families affected by low income and other social stressors.

Novo Nordisk secures first two wins in legal battle against compounding pharmacies, wellness centers

Federal judges have blocked two Florida wellness centers from using Novo Nordisk’s trademark to market compounded drugs containing its diabetes and weight loss blockbuster semaglutide.

February 10, 2024

Long-COVID recovery insight: Fatigue and cognitive deficits improve over two years

Study reveals improvements in cognitive deficits and fatigue among long-COVID patients over two years, with specific risk factors like depressive symptoms and old age predicting

February 6, 2024

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408 – Pharmaceutical Technology

An artist illustration of a doctor holding lungs. The FDA granted orphan-drug status for KB408 in September for the treatment of serious lung disease caused

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.